Get the Stockscreener App
5.215
3.06%
0.155
After Hours:
5.22
0.005
+0.10%
Immuneering Corp stock is traded at $5.215, with a volume of 458.90K.
It is up +3.06% in the last 24 hours and up +12.39% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$5.06
Open:
$5
24h Volume:
458.90K
Relative Volume:
0.31
Market Cap:
$337.40M
Revenue:
$500
Net Income/Loss:
$-54.44M
P/E Ratio:
-4.4733
EPS:
-1.1658
Net Cash Flow:
$-49.91M
1W Performance:
+15.12%
1M Performance:
+12.39%
6M Performance:
+1.86%
1Y Performance:
+38.70%
1-Day Range:
$4.99
$5.27
1-Week Range:
$4.55
$5.27
52-Week Range:
$3.25
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
5.215 | 327.37M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering Stock Price Forecast. Should You Buy IMRX? - StockInvest.us
HC Wainwright Estimates Immuneering Q3 Earnings - MarketBeat
Immuneering (NASDAQ:IMRX) Now Covered by HC Wainwright - MarketBeat
Immuneering (NASDAQ:IMRX) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
H.C. Wainwright initiates Immuneering stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Immuneering stock coverage with buy rating By Investing.com - Investing.com India
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Immuneering (NASDAQ:IMRX) Releases Earnings Results - MarketBeat
Immuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingView
Immuneering Q2 Loss Widens as Cash Runway Extends Into 2029 - Quiver Quantitative
Immuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingView
Immuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - quiverquant.com
Immuneering Corporation Q2 Net Income USD -17 - moomoo.com
Immuneering reports strong pancreatic cancer tr... - Pluang
IMRX|Immuneering Corp|Price:4.165|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Income Statement - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
IMRX|Immuneering Corp|Price:4.355|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX) Cash Flow - TradingKey
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Immuneering Corporation (IMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Immuneering reports preclinical data on atebimetinib in journal - Investing.com
IMRX Maintains by Needham -- Price Target Raised to $18.00 - GuruFocus
Immuneering (NASDAQ:IMRX) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Immuneering Corporation Announces Grants of Inducement Awards - The Manila Times
Form 4 Immuneering Corp For: 17 July By Investing.com - Investing.com Nigeria
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
Immuneering (IMRX) awards CFO Andrew Gengos 650,000 stock options - Stock Titan
Immuneering Corporation Announces Inducement Equity Grants to New CFO and Employee - Quiver Quantitative
Immuneering’s New CFO Gets 650,000-Share Option With $4.78 Exercise Price - Stock Titan
Immuneering Corp (IMRX) CFO discloses 225,000 Class A shares - Stock Titan
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Cantor Fitzgerald initiates Immuneering stock with overweight rating - Investing.com
If You Invested $1,000 in Immuneering Corp (IMRX) - Stock Titan
IMRXImmuneering Corp Latest SEC Filings - Finviz
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - Sahm
Immuneering Corporation (IMRX) Surges 5% as Stock Approaches Key Resistance LevelBull Pennant - dars.gov.et
Immuneering Corp. Class A Actuals & Estimates (NASDAQ:IMRX) - TradingView
IMRX Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Immuneering Corp For: 24 June By Investing.com - Investing.com Nigeria
Immuneering CEO Zeskind buys $10,948 in stock - Investing.com UK
Immuneering CEO Zeskind buys $10,948 in stock By Investing.com - Investing.com India
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immuneering Corp Stock (IMRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 15 '26 |
Buy |
4.15 |
6,035 |
25,045 |
382,531 |
| Brakewood Harold Eugene | Chief Business Officer |
Jan 16 '26 |
Buy |
4.76 |
5,250 |
24,990 |
11,050 |
| Schall Thomas J. | Director |
Jan 15 '26 |
Buy |
4.67 |
21,645 |
101,041 |
74,530 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jan 15 '26 |
Buy |
4.57 |
2,298 |
10,502 |
376,496 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jan 13 '26 |
Buy |
4.15 |
2,626 |
10,906 |
25,970 |
| Feinberg Peter | Director |
Jan 12 '26 |
Buy |
4.35 |
20,000 |
86,904 |
135,441 |
| Feinberg Peter | Director |
Oct 03 '25 |
Buy |
6.67 |
7,500 |
50,025 |
156,766 |
| Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):